Chelsea Therapeutics International Ltd
Chelsea Therapeutics International — Investor Presentation (February 2010)
28 slides from Chelsea Therapeutics International's investor presentation, Feb 9, 2010

Slide 1: February 2010
Exhibit 99.1 February 2010 © 2004-2010 Chelsea Therapeutics, Inc.

Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation is being provided for informational and discussion purposes. This presentationis not intended to provide andshouldnot be relied upon asinvestment advice or an opinion regarding the appropriateness or suitability of any investment. Nothing herein should be

Slide 3: Chelsea Overview
Chelsea Overview Developing Two Major Assets With Multiple, High-Potential Indications • Droxidopa: • NeurogenicOrthostatic Hypotension*(Northera™) • IntradialyticHypotension* • Fibromyalgia • Adult Attention Deficit and Hyperactivity Disorder • Freezing of Gait* • Chronic Fatigue • Other norepineph

Slide 4: Strong and Balanced Pipeline
Strong and Balanced Pipeline Preclinical Phase I Phase II Phase III Droxidopa: NOH (Northera) Study 302: PD, MSA, PAF Data: Q3 09 Study 301: PD, MSA, PAF Data: Q3 10 Study 306: PD Data: Q2 11 Fibromyalgia Data: Q4 10/Q1 11 IntradialyticHypotension Data: Q1 09 Metabolically Inert Antifolates: Rheumat

Slide 5: Neurogenic Orthostatic Hypotension
NeurogenicOrthostatic Hypotension • NeurogenicOrthostatic Hypotension (NOH) • Sudden fall in BP when standing from a sitting/lying position • Symptoms include lightheadedness, dizziness, falling, syncope • Caused by diminished synthesis and/or release of the NE used by autonomic nerves to regulate b

Slide 6: Northera Overview
NortheraOverview • “Prodrug”of Norepinephrine: Allows Autonomic Nervous System to Naturally Resume Normal Function • Sinemet®– a synthetic metabolic precursor Sinemet® Northera™ to Dopamine • Effectively treats movement disorders caused by Dopamine deficits • Northera™– a synthetic metabolic precurs

Slide 7: Original Northera Phase III Program: NOH
Original NortheraPhase III Program: NOH • Study302:PivotalProofof Efficacy– WithdrawalDesign • Study303:Long-Term Safety Extensionto Study 302– includes long-term efficacy assessment after 3 months • Study301:PivotalProofof Efficacy– Induction Design • Study 304: Long-Term Safety Extension to Study

Slide 8: Study 302: Design
Study 302: Design • Withdrawal design study in 101 NOH patients with primary autonomic failure • Primary Efficacy Measure: OHSA item 1 (dizziness) 600mg 500mg Randomization 400mg 300mg 200mg 100mg Northera™ Northera™ Visit Up to 2 weeks (open-label) 1 week (open- 2 weeks (blinded) label) 8

Slide 9: Study 302: Demographics
Study 302: Demographics All Patients PD Patients Only Placebo Northera Placebo Northera Number of 51 50 23 21 Patients Age 66.6 63.1 69.5 72.4 (Years) Gender 62.8 60.0 73.9 71.4 (% Male) Mean Northeraat 361 mg 412 mg 387 mg 352 mg Titration (tid) DDI Use 29 (57%) 28 (56%) 23 (100%) 21 (100%) 9

Slide 10: No Significant Adverse Events
No Significant Adverse Events • Most common adverse events reported: • Falls: 2% Northera, 12% placebo • Headache: 2% Northera, 8% placebo • Supine Hypertension: Number of Number of Placebo Northera BP (mm HG) Patients Patients 6 (12%) 180-200 3 (6%) ? 200 0 1 (2%) • Midodrinelabel: supine hypertens

Slide 11: Key Symptomatic Efficacy Outcome Measures
Key Symptomatic Efficacy Outcome Measures • Orthostatic Hypotension Questionnaire: OHQ • Orthostatic Hypotension Symptom Assessment: OHSA 1. Dizziness, lightheadedness, feeling faint, or feeling like you might blackout 2. Problems with vision (blurring, seeing spots, tunnel vision, etc.) 3. Weakness

Slide 12: Broad Symptomatic and Functional Benefits
Broad Symptomatic and Functional Benefits * p<0.05 ** p<0.01 Favors Northera Favors Placebo

Slide 13: Study 302: Benefit on OHQ Composite Scores
Study 302: Benefit on OHQ Composite Scores Composite Score Best Capture Full Therapeutic Benefit of Northera 13

Slide 14: Study 302: Results Summary
Study 302: Results Summary • Northera™treatment associated with positive trends in 13 of 14 prospectively identified individual outcome variables • 16 of 17 including composite scores • 5 prospectively defined endpoints achieved statistical significance • Symptomatic/functional benefit Scorecard Dro

Slide 15: Incorporating Key Findings from Study 302
Incorporating Key Findings from 302 • Met with FDA to DiscussResultsandKeyLearningsfrom Study302 • Provided all data and sensitivity testing on outcome scales • Indicate benefit of using OHQ composite score • Open Label Response Criteria Not Optimal Enrichment Technique • BP responders didn’t correl

Slide 16: History of Successful FDA Interactions
History of Successful FDA Interactions • Granted Orphan Status • Granted SPA for Study 301 • Granted Fast Track Status • Met with FDA in November 2009 • Granted Increase in Study 301 patient enrollment to 150 • Increases power/robustness of outcome and viability of overall NDA submission • Improves

Slide 17: Current Northera Phase III Program: NOH
Current NortheraPhase III Program: NOH • Study 302: Pivotal Proof of Efficacy Withdrawal – Design • Study303:Long-Term Safety Extensionto Study 302– includeslong-term efficacy assessment after 3 months • Study 301: Pivotal Proof of Efficacy Induction – Design Change in Primary Endpoint to OHQ compos

Slide 18: Study 301: Revised Design
Study 301: Revised Design • Inductiondesignstudyin150NOH patientswith primaryautonomicfailure • Primary efficacy measure: OHQ composite • Special Protocol Assessment 600mg 500mg Randomization 400mg Placebo 300mg Washout 200mg 100mg Visit Up to 2 weeks (open-label) 1 week (open- 1 weeks (blinded) lab

Slide 19: Study 306: NOH in Parkinson's Disease
Study 306: NOH in Parkinson’s Disease • Enriched Heterogeneous population: 84 PD Patients with NOH • Longer Treatment duration allows active arm to improve and placebo to fail • Primary efficacy measure: OHQ composite • Starting Q2 2010, top-line data Q2 2011 Visit 7 N= 42 Visit 1 Visit 2 Visit 3a,

Slide 20: Northera NOH Value Proposition
NortheraNOH Value Proposition • Differentiated Profile • Treats underlying cause of NOH • Ideal candidate for first line therapy • Benign safety profile a significant benefit for patients taking multiple medications • Significant Upside Potential: + ROW + QD Formulation + Better PD Efficacy + Midodr

Slide 21: Droxidopa: Label Expansion Opportunities
Droxidopa: Label Expansion Opportunities NorepinephrineRelated Disorders Intradialytic Fibromyalgia Adult Chronic Hypotension Attention Deficit Fatigue Disorder Syndrome Droxidopa Droxidopa + Carbidopa Droxidopa + Carbidopa Droxidopa + Carbidopa 15-25% of all Chronic Pain Second Most Debilitating he

Slide 22: Novel Antifolates with Blockbuster Potential
Novel Antifolateswith Blockbuster Potential • First non-metabolized oral antifolates • Engineered for improved safety and increased tolerability vs. methotrexate • Potential first line andcombination treatment for rheumatoid arthritis • Not competing with Biologics • Methotrexate(MTX) remains most w

Slide 23: CH-1504: Phase II Proof-of-Concept
CH-1504: Phase II Proof-of-Concept • 12-week trial comparing CH-1504 to MTX in 200 MTX naive RA patients • 0.25, 0.5 or 1.0 mg daily dose of CH-1504 vs. 20 mg weekly dose of MTX • Achieved Primary Objective by Demonstrating Comparable ACR 20 Response Rates To MTX and Improved Safety Profile • No Dro

Slide 24: CH-4051: Greater Efficacy/Safety
CH-4051: Greater Efficacy/Safety • Key preclinical findings suggests: • Superior preclinical efficacy to both CH-1504 MTX • Enzymatic activity (DHFR inhibition) • Uptake by Reduced Folate Carrier • Increases activity in CIA model over both CH-1504 and MTX • Improved safety/toxicity • Phase I SAD stu

Slide 25: CH-4051 Phase II: MTX Partial Responders RA
CH-4051 Phase II: MTX Partial Responders RA • 12-week, 5-arm trial comparing CH-4051 to MTX in 250 RA patients • MTX Partial Responders • Primary efficacy measure: ACR Hybrid Score • Starting Q2 2010, top-line data Q2 2011 N= 50 3.0 mg CH-4051/daily + FOLATE N= 50 3.0 mg CH-4051/daily + N= 50 1.0 mg

Slide 26: Efficacy Analysis Using Hybrid ACR
Efficacy Analysis Using Hybrid ACR • Hybrid ACR Score (hACR). • Endorsed by ACR, FDA and key opinion leaders • More sensitive to treatment effects than traditional ACR 20/50/70 • Starts with ACR 20/50/70 as a basis--permits greater precision than discrete ACR scores Example: If a patient meets tradi

Slide 27: Financial Summary
Financial Summary Capitalization as of January 31, 2009 Common Stock 33,500,406 Warrants 4,060,758 Options 4,606,430 Fully Diluted42,167,594 Cash as of September 30, 2009 $30 million Expected Q4 09 Cash$22 million 27

Slide 28: Looking Ahead....
Looking Ahead…. • Operational Focus • Drive NortheraRegistration Program/NDA • AdvanceCH-4051in RAandDroxidopain additionalindications • Executestrategic,cashgeneratinglicensing/partnershipopportunities • Upcoming Milestones Finalize Protocol Northera PIII: NOH Study 306 Q1 10 Top-line Results North
Source: SEC EDGAR · 8-K filed Feb 9, 2010
More decks from Chelsea Therapeutics International Ltd
Investor Presentation (July 2013)27 slides · Jul 9, 2013
Technical Presentation (December 2012)21 slides · Dec 5, 2012
Rodman and Renshaw Investor Conference 201226 slides · Sep 10, 2012
Investor Presentation (October 2011)30 slides · Oct 19, 2011
Investor Presentation (September 2011)28 slides · Sep 13, 2011
Technical Presentation (September 2010)27 slides · Sep 20, 2010